Antibody-drug conjugate · Cytotoxic, directed at B7-H3 (CD276) and DNA topoisomerase 1 (TOP1) · developed by BioNTech
Elfetabart drozuntecan is an antibody-drug conjugate in which a humanized antibody against B7-H3 (CD276) is linked by a cleavable linker to the topoisomerase-1 inhibitor P1021. After binding B7-H3-expressing tumor cells and internalization, the payload is released and inhibits DNA topoisomerase-1, leading to cell cycle arrest and apoptosis. It is studied in advanced solid tumors and metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07365995 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | Recruiting | BNTX |
| NCT06953089 | Phase 2 | Solid Tumors | Recruiting | BNTX |
| NCT05914116 | Phase 1/2 | Advanced Solid Tumors | Recruiting | BNTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsMetastatic Castration-resistant Prostate CancerSolid Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the BNTX page.
See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BNTX catalysts and pipeline →